Article Menu

Export Article

More by Authors Links

Article Data

  • Views 1756
  • Dowloads 136

Case Reports

Open Access

Complete response after pertuzumab + trastuzumab + docetaxel in metastatic Her2-positive breast cancer patients: review of four cases

  • F. Lai-Tiong1,*,

1Oncology Unit Gard Cancer Institute, Rue du Professeur Henri Pujol, Nîmes (France)

DOI: 10.12892/ejgo4026.2018 Vol.39,Issue 5,October 2018 pp.845-846

Published: 10 October 2018

*Corresponding Author(s): F. Lai-Tiong E-mail: florencelt@hotmail.fr

PDF (87.74 kB) View Full-text

Abstract

Her2-positive breast cancers represent about 20 percent of breast cancer patients. Her2-positive breast cancers have more aggressive and poorer prognosis. However, with the emergence of new therapies, outcomes have changed with improvement in survival. Pertuzumab is a new drug, a monoclonal antibody against Her2, available for use in the treatment of Her2-positive breast cancer.

Keywords

Pertuzumab; Her2-positive breast cancer; Metastases; Complete response.

Cite and Share

F. Lai-Tiong. Complete response after pertuzumab + trastuzumab + docetaxel in metastatic Her2-positive breast cancer patients: review of four cases. European Journal of Gynaecological Oncology. 2018. 39(5);845-846.

URL:

https://www.ejgo.net/articles/10.12892/ejgo4026.2018

References

[1] Baselga J., Cortés J., Kim S.B., Im S.A., Hegg R., Im Y.H., et al.: “Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer”. N. Engl. J. Med., 2012, 366, 109.

[2] Swain S.M., Baselga J., Kim S.B., Ro J., Semiglazov V., Campone M., et al.: “Pertuzumab, trastuzumab, and docetaxel in Her2-positive metastatic breast cancer”. N. Engl. J. Med., 2015, 372, 724.

[3] Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al.: “Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2”. N. Engl. J. Med., 2001, 344, 783.

Submission Turnaround Time

Top